

Junzo Hamanishi

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/6104202/publications.pdf>

Version: 2024-02-01

125
papers

8,226
citations

126708

33
h-index

49773

87
g-index

130
all docs

130
docs citations

130
times ranked

12555
citing authors

#	ARTICLE	IF	CITATIONS
1	Tertiary lymphoid structures are associated with favorable survival outcomes in patients with endometrial cancer. <i>Cancer Immunology, Immunotherapy</i> , 2022, 71, 1431-1442.	2.0	15
2	Radiomic machine learning for pretreatment assessment of prognostic risk factors for endometrial cancer and its effects on radiologists' decisions of deep myometrial invasion. <i>Magnetic Resonance Imaging</i> , 2022, 85, 161-167.	1.0	17
3	B7-H3 Suppresses Antitumor Immunity via the CCL2â€“CCR2â€“M2 Macrophage Axis and Contributes to Ovarian Cancer Progression. <i>Cancer Immunology Research</i> , 2022, 10, 56-69.	1.6	49
4	Changes in HPV16/18 Prevalence among Unvaccinated Women with Cervical Intraepithelial Neoplasia in Japan: Assessment of Herd Effects following the HPV Vaccination Program. <i>Vaccines</i> , 2022, 10, 188.	2.1	2
5	Reply to D.-C. Mo et al. <i>Journal of Clinical Oncology</i> , 2022, 40, 523-524.	0.8	1
6	Immunosuppressive tumor microenvironment in Uterine Serous Carcinoma via CCL7 signal with myeloid-derived suppressor cells. <i>Carcinogenesis</i> , 2022, , .	1.3	2
7	Feasibility of Laparoscopic Para-Aortic Lymphadenectomy for Locally Advanced Cervical Cancer. <i>Journal of the Society of Laparoendoscopic Surgeons</i> , 2022, 26, e2021.00096.	0.5	0
8	CXCL13-producing CD4+ T cells accumulate in the early phase of tertiary lymphoid structures in ovarian cancer. <i>JCI Insight</i> , 2022, 7, .	2.3	48
9	Utility of Homologous Recombination Deficiency Biomarkers Across Cancer Types. <i>JCO Precision Oncology</i> , 2022, , .	1.5	18
10	Remote solid cancers rewire hepatic nitrogen metabolism via host nicotinamide-N-methyltransferase. <i>Nature Communications</i> , 2022, 13, .	5.8	16
11	Polarity switching of ovarian cancer cell clusters via <scp>SRC</scp> family kinase is involved in the peritoneal dissemination. <i>Cancer Science</i> , 2022, 113, 3437-3448.	1.7	3
12	Bevacizumab-associated events in Japanese women with cervical cancer: a multi-institutional survey of Obstetrical Gynecological Society of Kinki district, Japan. <i>International Journal of Clinical Oncology</i> , 2021, 26, 598-605.	1.0	6
13	Three cases of seromucinous carcinoma of the ovary arising in endometriotic cysts. <i>International Cancer Conference Journal</i> , 2021, 10, 46-53.	0.2	0
14	Intracervical elastomeric sealant in an ex vivo model. <i>Journal of Maternal-Fetal and Neonatal Medicine</i> , 2021, 34, 1109-1111.	0.7	2
15	Phase 2 single-arm study on the efficacy and safety of niraparib in Japanese patients with heavily pretreated, homologous recombination-deficient ovarian cancer. <i>Journal of Gynecologic Oncology</i> , 2021, 32, e16.	1.0	8
16	Tumor Immune Microenvironment during Epithelialâ€“Mesenchymal Transition. <i>Clinical Cancer Research</i> , 2021, 27, 4669-4679.	3.2	138
17	Oncofertility care in young women and the outcomes of pregnancy over the last 5ÂŹyears. <i>Future Science OA</i> , 2021, 7, FSO680.	0.9	4
18	Acquired Evolution of Mitochondrial Metabolism Regulated by HNF1B in Ovarian Clear Cell Carcinoma. <i>Cancers</i> , 2021, 13, 2413.	1.7	8

#	ARTICLE	IF	CITATIONS
19	Sebaceous carcinoma of the vulva treated with sentinel lymph node biopsy: a case report and literature review. <i>International Cancer Conference Journal</i> , 2021, 10, 239-243.	0.2	5
20	Combination of gene set signatures correlates with response to nivolumab in platinum-resistant ovarian cancer. <i>Scientific Reports</i> , 2021, 11, 11427.	1.6	3
21	A Case of Torsion in an Otherwise-Normal Ovary with a Giant Hematosalpinx Larger than Enlarged Ovary: Utilization of Diagnostic Laparoscopy for the Accurate Diagnosis. <i>Case Reports in Obstetrics and Gynecology</i> , 2021, 2021, 1-5.	0.2	0
22	A 36â€‰%kg Giant Ovarian Fibroma with Meigs Syndrome: A Case Report and Literature Review of Extremely Giant Ovarian Tumor. <i>Case Reports in Obstetrics and Gynecology</i> , 2021, 2021, 1-8.	0.2	4
23	A Novel Direct Approach to the Deep Uterine Vein in Laparoscopic Radical Hysterectomy. <i>Journal of Minimally Invasive Gynecology</i> , 2021, 28, 1444-1445.	0.3	0
24	Utility of Homologous Recombination Deficiency Biomarkers Across Cancer Types. <i>JCO Precision Oncology</i> , 2021, 5, 1270-1280.	1.5	9
25	Nivolumab Versus Gemcitabine or Pegylated Liposomal Doxorubicin for Patients With Platinum-Resistant Ovarian Cancer: Open-Label, Randomized Trial in Japan (NINJA). <i>Journal of Clinical Oncology</i> , 2021, 39, 3671-3681.	0.8	84
26	PK2 leads to cisplatin resistance through suppression of mitochondrial function in ovarian clear cell carcinoma. <i>Cancer Science</i> , 2021, 112, 4627-4640.	1.7	15
27	Phase 2 single-arm study on the safety of maintenance niraparib in Japanese patients with platinum-sensitive relapsed ovarian cancer. <i>Journal of Gynecologic Oncology</i> , 2021, 32, e21.	1.0	7
28	Superradical Hysterectomy for Cervical Cancer as an Alternative to the Usual Okabayashi-Type Radical Hysterectomy. <i>The Surgery Journal</i> , 2021, 7, S108-S114.	0.3	0
29	Fertility preservation of polypoid endometriosis: Case series and literature review. <i>Journal of Obstetrics and Gynaecology Research</i> , 2021, , .	0.6	4
30	Novel subtype of atonic postpartum hemorrhage: dynamic computed tomography evaluation of bleeding characteristics and the uterine cavity. <i>Journal of Maternal-Fetal and Neonatal Medicine</i> , 2020, 33, 3286-3292.	0.7	12
31	Prognostic utility of FDG PET/CT in advanced ovarian, fallopian and primary peritoneal high-grade serous cancer patients before and after neoadjuvant chemotherapy. <i>Annals of Nuclear Medicine</i> , 2020, 34, 128-135.	1.2	10
32	UGT1A1 polymorphism has a prognostic effect in patients with stage IB or II uterine cervical cancer and one or no metastatic pelvic nodes receiving irinotecan chemotherapy: a retrospective study. <i>BMC Cancer</i> , 2020, 20, 729.	1.1	7
33	Two Cases of Ectopic Pregnancy Mimicking Gestational Trophoblastic Disease. <i>Case Reports in Obstetrics and Gynecology</i> , 2020, 2020, 1-4.	0.2	3
34	Low-Grade Endometrial Stromal Sarcoma with a Nodule-in-Nodule Appearance in Preoperative Magnetic Resonance Images. <i>Case Reports in Obstetrics and Gynecology</i> , 2020, 2020, 1-7.	0.2	3
35	Anti-VEGF therapy resistance in ovarian cancer is caused by GM-CSF-induced myeloid-derived suppressor cell recruitment. <i>British Journal of Cancer</i> , 2020, 122, 778-788.	2.9	61
36	Mucinous adenocarcinoma, gastric type of the uterine cervix: clinical features and HER2 amplification. <i>Medical Molecular Morphology</i> , 2019, 52, 52-59.	0.4	25

#	ARTICLE	IF	CITATIONS
37	Analytical performance of a new automated chemiluminescent magnetic immunoassays for soluble PD-1, PD-L1, and CTLA-4 in human plasma. <i>Scientific Reports</i> , 2019, 9, 10144.	1.6	29
38	Acquisition of a side population fraction augments malignant phenotype in ovarian cancer. <i>Scientific Reports</i> , 2019, 9, 14215.	1.6	11
39	Phosphorylation of STAT1 serine 727 enhances platinum resistance in uterine serous carcinoma. <i>International Journal of Cancer</i> , 2019, 145, 1635-1647.	2.3	6
40	Hysteroscopic morphological pattern reflects histological grade of endometrial cancer. <i>Journal of Obstetrics and Gynaecology Research</i> , 2019, 45, 1479-1487.	0.6	9
41	Endovascular trophoblast expresses CD59 to evade complement-dependent cytotoxicity. <i>Molecular and Cellular Endocrinology</i> , 2019, 490, 57-67.	1.6	23
42	VISTA expressed in tumour cells regulates T cell function. <i>British Journal of Cancer</i> , 2019, 120, 115-127.	2.9	133
43	The efficacy of secondary cytoreductive surgery for recurrent ovarian, tubal, or peritoneal cancer in Tian-model low-risk patients. <i>Journal of Gynecologic Oncology</i> , 2019, 30, e100.	1.0	9
44	Laparoscopic conservative surgery for bilateral massive ovarian edema presenting with hemoperitoneum. <i>Japanese Journal of Gynecologic and Obstetric Endoscopy</i> , 2019, 35, 119-122.	0.0	0
45	Breakthrough of Cancer Therapies Targeting PD-1 Signal Pathway. <i>Trends in the Sciences</i> , 2019, 24, 2_20-2_24.	0.0	0
46	Tight systolic blood pressure control early in pregnancy improves pregnancy outcomes in women with chronic hypertension. <i>Hypertension Research in Pregnancy</i> , 2019, 7, 75-81.	0.1	3
47	Snail promotes ovarian cancer progression by recruiting myeloid-derived suppressor cells via CXCR2 ligand upregulation. <i>Nature Communications</i> , 2018, 9, 1685.	5.8	211
48	Feasibility of laparoscopic surgery for obese patients with uterine corpus cancer. <i>Japanese Journal of Gynecologic and Obstetric Endoscopy</i> , 2018, 34, 159-164.	0.0	0
49	Antitumor Effect of Nivolumab on Subsequent Chemotherapy for Platinum-Resistant Ovarian Cancer. <i>Oncologist</i> , 2018, 23, 1382-1384.	1.9	14
50	Genomics to immunotherapy of ovarian clear cell carcinoma: Unique opportunities for management. <i>Gynecologic Oncology</i> , 2018, 151, 381-389.	0.6	99
51	The effect of the type of dietary protein on the development of ovarian cancer. <i>Oncotarget</i> , 2018, 9, 23987-23999.	0.8	11
52	An experience of second-trimester anhydramnios salvaged by single amnioinfusion. <i>Journal of Medical Ultrasonics (2001)</i> , 2018, 45, 525-527.	0.6	1
53	Host expression of PD-L1 determines efficacy of PD-L1 pathway blockade-mediated tumor regression. <i>Journal of Clinical Investigation</i> , 2018, 128, 805-815.	3.9	423
54	Successful management of intraoperative haemorrhage during emergency cervical cerclage using balloon tamponade. <i>Journal of Obstetrics and Gynaecology</i> , 2017, 37, 523-524.	0.4	1

#	ARTICLE	IF	CITATIONS
55	Cancer immunotherapies targeting the PD-1 signaling pathway. <i>Journal of Biomedical Science</i> , 2017, 24, 26.	2.6	501
56	Exome Sequencing Landscape Analysis in Ovarian Clear Cell Carcinoma Shed Light on Key Chromosomal Regions and Mutation Gene Networks. <i>American Journal of Pathology</i> , 2017, 187, 2246-2258.	1.9	104
57	Expression of Vascular Endothelial Growth Factor in Ovarian Cancer Inhibits Tumor Immunity through the Accumulation of Myeloid-Derived Suppressor Cells. <i>Clinical Cancer Research</i> , 2017, 23, 587-599.	3.2	213
58	A case of complete hydatidiform mole with coexistent fetus developing hypertension and acute heart failure. <i>Hypertension Research in Pregnancy</i> , 2017, 5, 20-23.	0.1	0
59	Distinct preoperative clinical features predict four histopathological subtypes of high-grade serous carcinoma of the ovary, fallopian tube, and peritoneum. <i>BMC Cancer</i> , 2017, 17, 580.	1.1	14
60	Unenhanced region on magnetic resonance imaging represents tumor progression in uterine carcinosarcoma. <i>Journal of Gynecologic Oncology</i> , 2017, 28, e62.	1.0	4
61	Combination of Aprepitant, Azasetron, and Dexamethasone as Antiemetic Prophylaxis in Women with Gynecologic Cancers Receiving Paclitaxel/Carboplatin Therapy. <i>Medical Science Monitor</i> , 2017, 23, 826-833.	0.5	3
62	Immunology and Immunotherapy in Ovarian Cancer. <i>Comprehensive Gynecology and Obstetrics</i> , 2017, , 225-242.	0.0	2
63	Immunotherapy for Gynecologic Cancer. <i>Comprehensive Gynecology and Obstetrics</i> , 2017, , 69-85.	0.0	0
64	Groin lymph node detection and sentinel lymph node biopsy in vulvar cancer. <i>Journal of Gynecologic Oncology</i> , 2016, 27, e57.	1.0	10
65	Magnetic resonance imaging findings and prognosis of gastric-type mucinous adenocarcinoma (minimal deviation adenocarcinoma or adenoma malignum) of the uterine corpus: Two case reports. <i>Molecular and Clinical Oncology</i> , 2016, 4, 699-704.	0.4	12
66	Dual Faces of IFN γ in Cancer Progression: A Role of PD-L1 Induction in the Determination of Pro- and Antitumor Immunity. <i>Clinical Cancer Research</i> , 2016, 22, 2329-2334.	3.2	309
67	Immune checkpoint inhibition in ovarian cancer. <i>International Immunology</i> , 2016, 28, 339-348.	1.8	122
68	The BMP signaling pathway leads to enhanced proliferation in serous ovarian cancer-A potential therapeutic target. <i>Molecular Carcinogenesis</i> , 2016, 55, 335-345.	1.3	33
69	Clinical efficacy of neoadjuvant chemotherapy with irinotecan (CPT-11) and nedaplatin followed by radical hysterectomy for locally advanced cervical cancer. <i>Journal of International Medical Research</i> , 2016, 44, 346-356.	0.4	5
70	Prediction of taxane and platinum sensitivity in ovarian cancer based on gene expression profiles. <i>Gynecologic Oncology</i> , 2016, 141, 49-56.	0.6	33
71	Establishment of a Novel Histopathological Classification of High-Grade Serous Ovarian Carcinoma Correlated with Prognostically Distinct Gene Expression Subtypes. <i>American Journal of Pathology</i> , 2016, 186, 1103-1113.	1.9	71
72	PD-1/PD-L1 blockade in cancer treatment: perspectives and issues. <i>International Journal of Clinical Oncology</i> , 2016, 21, 462-473.	1.0	255

#	ARTICLE	IF	CITATIONS
73	Anti-PD-L1/PD-1 immune therapies in ovarian cancer: basic mechanism and future clinical application. <i>International Journal of Clinical Oncology</i> , 2016, 21, 456-461.	1.0	29
74	Specific gene signatures and oligo clonal expansion of b cell repertoire with responders of anti-PD-1 antibody, nivolumab for ovarian cancer: Novel predictive biomarkers.. <i>Journal of Clinical Oncology</i> , 2016, 34, 5513-5513.	0.8	1
75	Comprehensive assessment of the expression of the SWI/SNF complex defines two distinct prognostic subtypes of ovarian clear cell carcinoma. <i>Oncotarget</i> , 2016, 7, 54758-54770.	0.8	25
76	Suppression of <i>ABHD2</i> , identified through a functional genomics screen, causes anoikis resistance, chemoresistance and poor prognosis in ovarian cancer. <i>Oncotarget</i> , 2016, 7, 47620-47636.	0.8	28
77	Genomic profile predicts the efficacy of neoadjuvant chemotherapy for cervical cancer patients. <i>BMC Cancer</i> , 2015, 15, 739.	1.1	10
78	Hepatocyte nuclear factor-1 β (HNF1 β) promotes glucose uptake and glycolytic activity in ovarian clear cell carcinoma. <i>Molecular Carcinogenesis</i> , 2015, 54, 35-49.	1.3	57
79	Invasion of uterine cervical squamous cell carcinoma cells is facilitated by locoregional interaction with cancer-associated fibroblasts via activating transforming growth factor-beta. <i>Gynecologic Oncology</i> , 2015, 136, 104-111.	0.6	21
80	IFN- γ from lymphocytes induces PD-L1 expression and promotes progression of ovarian cancer. <i>British Journal of Cancer</i> , 2015, 112, 1501-1509.	2.9	533
81	Safety and Antitumor Activity of Anti-PD-1 Antibody, Nivolumab, in Patients With Platinum-Resistant Ovarian Cancer. <i>Journal of Clinical Oncology</i> , 2015, 33, 4015-4022.	0.8	924
82	Chemotherapy Induces Programmed Cell Death-Ligand 1 Overexpression via the Nuclear Factor- κ B to Foster an Immunosuppressive Tumor Microenvironment in Ovarian Cancer. <i>Cancer Research</i> , 2015, 75, 5034-5045.	0.4	439
83	Menstrual cyclic change of metastin/GPR54 in endometrium. <i>Medical Molecular Morphology</i> , 2015, 48, 76-84.	0.4	20
84	Durable tumor remission in patients with platinum-resistant ovarian cancer receiving nivolumab.. <i>Journal of Clinical Oncology</i> , 2015, 33, 5570-5570.	0.8	16
85	Metabolic alterations caused by HNF1 β expression in ovarian clear cell carcinoma contribute to cell survival. <i>Oncotarget</i> , 2015, 6, 26002-26017.	0.8	47
86	Abstract A25: Dysregulation of MYC via STAT1 promotes tumor progression in serous papillary endometrial cancer. , 2015, , .		0
87	Transverse fundal uterine incision for delivery of extremely low birth-weight infants. <i>Journal of Maternal-Fetal and Neonatal Medicine</i> , 2014, 27, 1285-1287.	0.7	4
88	Treatment decision-making for post-partum hemorrhage using dynamic contrast-enhanced computed tomography. <i>Journal of Obstetrics and Gynaecology Research</i> , 2014, 40, 67-74.	0.6	15
89	Clinical approaches to treating papillary squamous cell carcinoma of the uterine cervix. <i>BMC Cancer</i> , 2014, 14, 784.	1.1	12
90	STAT1 Drives Tumor Progression in Serous Papillary Endometrial Cancer. <i>Cancer Research</i> , 2014, 74, 6519-6530.	0.4	66

#	ARTICLE	IF	CITATIONS
91	Efficacy and safety of anti-PD-1 antibody (Nivolumab: BMS-936558, ONO-4538) in patients with platinum-resistant ovarian cancer.. <i>Journal of Clinical Oncology</i> , 2014, 32, 5511-5511.	0.8	33
92	A novel diagnostic criterion for lymph node metastasis in cervical cancer using multi-detector computed tomography. <i>Gynecologic Oncology</i> , 2013, 131, 701-707.	0.6	13
93	Ileal perforation and massive intestinal haemorrhage from endometriosis in pregnancy: case report and literature review. <i>European Journal of Obstetrics, Gynecology and Reproductive Biology</i> , 2013, 170, 20-24.	0.5	27
94	Serial magnetic resonance imaging of placenta percreta with bladder involvement during pregnancy and postpartum: A case report. <i>Journal of Obstetrics and Gynaecology Research</i> , 2013, 39, 359-363.	0.6	9
95	Pyomyoma during pregnancy: A case report and review of the literature. <i>Journal of Obstetrics and Gynaecology Research</i> , 2013, 39, 383-389.	0.6	27
96	Utilization of genomic signatures to identify high efficacy candidate drugs for chemorefractory endometrial cancers. <i>International Journal of Cancer</i> , 2013, 133, 2234-2244.	2.3	11
97	Recurrence of a carcinoid tumor of the ovary 13 years after the primary surgery: A case report. <i>Oncology Letters</i> , 2013, 6, 1241-1244.	0.8	14
98	PD-L1 on Tumor Cells Is Induced in Ascites and Promotes Peritoneal Dissemination of Ovarian Cancer through CTL Dysfunction. <i>Clinical Cancer Research</i> , 2013, 19, 1363-1374.	3.2	196
99	Cervical clamp with ring forceps to prevent prolapse of an intrauterine balloon in the management of postpartum hemorrhage. <i>Journal of Obstetrics and Gynaecology Research</i> , 2013, 39, 733-737.	0.6	17
100	Clinical Management of Ovarian Endometriotic Cyst (Chocolate Cyst): Diagnosis, Medical Treatment, and Minimally Invasive Surgery. <i>Current Obstetrics and Gynecology Reports</i> , 2012, 1, 16-24.	0.3	6
101	The activated transforming growth factor beta signaling pathway in peritoneal metastases is a potential therapeutic target in ovarian cancer. <i>International Journal of Cancer</i> , 2012, 130, 20-28.	2.3	62
102	Ovarian clear cell carcinoma as a stress-responsive cancer: Influence of the microenvironment on the carcinogenesis and cancer phenotype. <i>Cancer Letters</i> , 2011, 310, 129-133.	3.2	37
103	The comprehensive assessment of local immune status of ovarian cancer by the clustering of multiple immune factors. <i>Clinical Immunology</i> , 2011, 141, 338-347.	1.4	70
104	Distinguishing primary from secondary mucinous ovarian tumors: an algorithm using the novel marker DPEP1. <i>Modern Pathology</i> , 2011, 24, 267-276.	2.9	13
105	GPR54 Is a Target for Suppression of Metastasis in Endometrial Cancer. <i>Molecular Cancer Therapeutics</i> , 2011, 10, 580-590.	1.9	37
106	Oct4 Expression in Immature Teratoma of the Ovary. <i>American Journal of Surgical Pathology</i> , 2010, 34, 1842-1848.	2.1	51
107	Suppression of Metastatic Murine Ovarian Cancer Cells by Transduced Embryonic Progenitor Cells. <i>Hormones and Cancer</i> , 2010, 1, 291-296.	4.9	3
108	Sorafenib efficacy in ovarian clear cell carcinoma revealed by transcriptome profiling. <i>Cancer Science</i> , 2010, 101, 2658-2663.	1.7	32

#	ARTICLE	IF	CITATIONS
109	Identification of an ovarian clear cell carcinoma gene signature that reflects inherent disease biology and the carcinogenic processes. <i>Oncogene</i> , 2010, 29, 1741-1752.	2.6	165
110	Clinical significance of the NKG2D ligands, MICA/B and ULBP2 in ovarian cancer: high expression of ULBP2 is an indicator of poor prognosis. <i>Cancer Immunology, Immunotherapy</i> , 2009, 58, 641-652.	2.0	144
111	Activated Local Immunity by CCL19-Transduced Embryonic Endothelial Progenitor Cells Suppresses Metastasis of Murine Ovarian Cancer. <i>Stem Cells</i> , 2009, 28, N/A-N/A.	1.4	42
112	Classification using hierarchical clustering of tumor-infiltrating immune cells identifies poor prognostic ovarian cancers with high levels of COX expression. <i>Modern Pathology</i> , 2009, 22, 373-384.	2.9	34
113	Intractable recurrent cervical cancer with pelvic bone involvement successfully treated with external hemipelvectomy. <i>Journal of Obstetrics and Gynaecology Research</i> , 2008, 34, 112-116.	0.6	7
114	Contents of Endometriotic Cysts, Especially the High Concentration of Free Iron, Are a Possible Cause of Carcinogenesis in the Cysts through the Iron-Induced Persistent Oxidative Stress. <i>Clinical Cancer Research</i> , 2008, 14, 32-40.	3.2	259
115	Malignant transformation of mature cystic teratoma of the ovary including three cases occurring during follow-up period. <i>Oncology Reports</i> , 2008, , .	1.2	13
116	Immunostimulatory effect of Fms-like tyrosine kinase 3 ligand on peripheral monocyte-derived dendritic cells and natural killer cells: utilization for ovarian cancer treatment. <i>Oncology Reports</i> , 2008, 19, 505-15.	1.2	7
117	Malignant transformation of mature cystic teratoma of the ovary including three cases occurring during follow-up period. <i>Oncology Reports</i> , 2008, 19, 705-11.	1.2	12
118	Programmed cell death 1 ligand 1 and tumor-infiltrating CD8+ T lymphocytes are prognostic factors of human ovarian cancer. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2007, 104, 3360-3365.	3.3	1,308
119	Immortalized ovarian surface epithelial cells acquire tumorigenicity by Acrogranin gene overexpression. <i>Oncology Reports</i> , 2007, , .	1.2	9
120	Immortalized ovarian surface epithelial cells acquire tumorigenicity by Acrogranin gene overexpression. <i>Oncology Reports</i> , 2007, 17, 329-33.	1.2	20
121	Embryogenesis of fused umbilical arteries in human embryos. <i>American Journal of Obstetrics and Gynecology</i> , 2005, 193, 1709-1715.	0.7	7
122	Spontaneous regression of congenital cystic adenomatoid malformation of the lung: Longitudinal examinations by magnetic resonance imaging. <i>Congenital Anomalies (discontinued)</i> , 2005, 45, 157-160.	0.3	5
123	A case of successful management of maternal septic shock with multiple organ failure following amniocentesis at midgestation. <i>Journal of Obstetrics and Gynaecology Research</i> , 2002, 28, 258-261.	0.6	15
124	Immunostimulatory effect of Fms-like tyrosine kinase 3 ligand on peripheral monocyte-derived dendritic cells and natural killer cells: Utilization for ovarian cancer treatment. <i>Oncology Reports</i> , 0, , .	1.2	2
125	Development of healthy lifestyle consciousness index for gynecological cancer patients. <i>Supportive Care in Cancer</i> , 0, , .	1.0	0